Cardinal Health Q2 Revenue Jumps 19% to $61B; Specialty, Theranostics Fuel Profit Growth
Cardinal Health’s fiscal Q2 revenue rose 19% to $61 billion with segment profit up 29%, driven by specialty distribution and theranostics growth within adjacent businesses that saw 34% revenue and 52% profit gains. The GMPD segment swung to $37 million profit year-over-year but pharma profit growth is projected to moderate to mid-teens.
1. Strong Q2 Financial Performance
Cardinal Health posted fiscal Q2 revenue of $61 billion, up 19% year-over-year, with segment profit rising 29% on strong demand across brand, specialty and generics distribution. The company’s shares have surged 49.2% over the past six months, reflecting market confidence in its growth trajectory.
2. Adjacent Businesses Drive Diversification
The company’s “Other” businesses—Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight Logistics—delivered 34% revenue growth and 52% profit growth, driven by theranostics demand that generated over 30% revenue growth. Management expects specialty revenues to exceed $50 billion in fiscal 2026, underlining the pivot to higher-margin therapies.
3. GMPD Segment Turnaround and Future Outlook
The Global Medical Products and Distribution segment turned profitable, with profit rising to $37 million from $18 million a year ago, supported by operational restructuring and supply chain investments. However, pending tariff costs on medical products and anticipated mid-teens profit growth in the pharma segment signal potential moderation in earnings momentum.